Department of Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Chem Biol Interact. 2011 Jul 15;192(3):233-42. doi: 10.1016/j.cbi.2011.03.014. Epub 2011 Mar 30.
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion and/or action. One of the most important complications of this metabolic disease is diabetic nephropathy. Hyperglycemia promotes oxidative stress and hence generation of reactive oxygen species (ROS), which is known to play a crucial role in the pathogenesis of diabetic nephropathy. Recent studies have established that metformin, an oral hypoglycemic drug, possesses antioxidant effects. However, whether metformin can protect against diabetic nephropathy has not been reported before. The overall objectives of the present study are to elucidate the potential nephroprotective effect of metformin in a rat diabetic nephropathy model and explore the exact underlying mechanism(s) involved. The effect of metformin on the biochemical changes associated with hyperglycemia induced by streptozotocin was investigated in rat kidney tissues. In addition, energy nucleotides (AMP and ATP), and Acetyl-CoA in the kidney homogenates and mitochondria, and the mRNA expression of oxidative stress and pro-inflammatory mediators were assessed. Our results showed that treatment of normoglycemic rats with metformin caused significant increase in ATP, Acetyl-CoA, and CoA-SH contents in kidney homogenates and mitochondria along with profound decrease in AMP level. On the other hand, treatment of diabetic nephropathy rats with metformin normalized all biochemical changes and the energy status in kidney tissues. At the transcriptional levels, metformin treatment caused significant restoration in diabetic nephropathy-induced oxidative stress mRNA levels, particularly GSTα, NQO1, and CAT genes, whereas inhibited TNF-α and IL-6 pro-inflammatory genes. Our data lend further credence for the contribution of metformin in the nephroprotective effect in addition to its well known hypoglycemic action.
糖尿病是一组以高血糖为特征的代谢性疾病,由胰岛素分泌和/或作用缺陷引起。这种代谢性疾病最重要的并发症之一是糖尿病肾病。高血糖会促进氧化应激,从而产生活性氧(ROS),这被认为在糖尿病肾病的发病机制中起着至关重要的作用。最近的研究已经证实,口服降糖药二甲双胍具有抗氧化作用。然而,二甲双胍是否能预防糖尿病肾病尚未有报道。本研究的总体目标是阐明二甲双胍在糖尿病肾病大鼠模型中的潜在肾保护作用,并探讨其确切的作用机制。研究了二甲双胍对链脲佐菌素诱导的高血糖相关生化变化的影响。此外,还评估了肾脏匀浆和线粒体中的能量核苷酸(AMP 和 ATP)和乙酰辅酶 A 以及氧化应激和促炎介质的 mRNA 表达。我们的结果表明,二甲双胍治疗正常血糖大鼠可显著增加肾脏匀浆和线粒体中的 ATP、乙酰辅酶 A 和 CoA-SH 含量,同时显著降低 AMP 水平。另一方面,二甲双胍治疗糖尿病肾病大鼠可使肾脏组织中的所有生化变化和能量状态正常化。在转录水平上,二甲双胍治疗可显著恢复糖尿病肾病诱导的氧化应激 mRNA 水平,特别是 GSTα、NQO1 和 CAT 基因,同时抑制 TNF-α 和 IL-6 促炎基因。我们的数据进一步证实了二甲双胍除了具有众所周知的降血糖作用外,在肾保护作用中的贡献。